價格 | ¥130 | ¥276 | ¥397 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:3,4-二羥基苯甲羥肟酸 | 英文名稱:Didox |
CAS:69839-83-4 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 96.85% | 產(chǎn)品類別: 抑制劑 |
貨號: T7525 |
名稱 | Didox |
描述 | Didox (NSC-324360) is a synthetic ribonucleotide reductase (RR) inhibitor that has been found to reduce the levels of oxidative injury markers in the brains of HIV patients with dementia. |
細(xì)胞實(shí)驗(yàn) | The cells were seeded in a 96-well plate (at a density of 2 × 10^3 cells for HA22T/VGH;?1.5 × 103 cells for HuH7) and exposed to various concentrations of didox and only HA22T/VGH also to hydroxyurea, DFO or DFP (0, 1, 10, 25, 50, 100, 200 and 500 μM) for 24, 48 and 72 h. In other experiments, HA22T/VGH were seeded in 96-well plates and treated with a single dose of didox, HU, DFO, DFP alone or in combination with increasing doses of FAC (25, 50, 100, 200 and 400 μM) for 48–72 h. In other type of treatment,?HA22T/VGH cells were or pre-treated for 16 h with a single dose of didox (200 μM) and then treated in combination with FAC (400–800 μM) or directly in combination didox-FAC for 48–72 h.Cell viability was evaluated with an MTT assay.?After the indicated time points and treatments, the supernatant was removed and 100 μL of the MTT solution (0.5 mg/mL) diluted in the cell medium was added to the wells.?After 3.5 h of incubation at 37 °C and 5% CO2, the MTT medium was removed and 75 μL of DMSO was added to each well.?Plates were shaken for 15 min at 37 °C until complete dissolution and absorbance was measured at 540 nm emission wavelengths.?Average percentage of cell viability at each concentration was calculated using Microsoft Excel 2016 software[1]. |
體外活性 | Didox引起細(xì)胞死亡,而這一效應(yīng)通過補(bǔ)充鐵質(zhì)得到抑制。Didox處理導(dǎo)致細(xì)胞鐵含量、TfR1和鐵蛋白水平發(fā)生變化,這與鐵螯合劑deferoxamine(DFO)和deferiprone(DFP)造成的效果相當(dāng)。Didox是一種雙齒鐵螯合劑,具有兩個理論上可能的結(jié)合位點(diǎn),其中以catechol基團(tuán)的兩個羥基作為配體的是更可能的一種。Didox的鐵螯合特性可能通過阻斷Tyr122上酪氨酸自由基的形成(如HU)以及通過捕獲RRM2(對其活性至關(guān)重要)和細(xì)胞增殖所需的鐵,從而對其抗腫瘤活性貢獻(xiàn)。 |
體內(nèi)活性 | Didox處理小鼠源骨髓誘發(fā)的肥大細(xì)胞(BMMC)時,降低了IgE刺激下的脫顆粒反應(yīng)和包括IL-6、IL-13、TNF及MIP-1a (CCL3)在內(nèi)的細(xì)胞因子產(chǎn)生[2]。 |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 100 mg/mL (591.26 mM) |
關(guān)鍵字 | Didox | NSC 324360 | Inhibitor | DNA/RNA Synthesis | inhibit | NSC324360 |
相關(guān)產(chǎn)品 | N-Nitrosodiethylamine | Acyclovir | Guanidine hydrochloride | Trimethoprim | Procaine | Pemetrexed | Folic acid | Resveratrol | 5-Fluorouracil | Temozolomide | Thymidine | Ribavirin |
相關(guān)庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌化合物庫 | 已知活性化合物庫 | ReFRAME 相關(guān)化合物庫 | 抗衰老化合物庫 | 臨床前化合物庫 | 抗病毒庫 | DNA 損傷和修復(fù)分子庫 | 人代謝物化合物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報(bào)價日期 | |
---|---|---|---|---|
詢價 |
VIP5年
|
湖北惠擇普醫(yī)藥科技有限公司
|
2024-11-03 | |
詢價 |
VIP3年
|
唐緣生命科學(xué)(上海)有限公司
|
2024-12-15 | |
詢價 |
VIP6年
|
武漢卡諾斯科技有限公司
|
2024-12-30 | |
詢價 |
VIP6年
|
成都彼樣生物科技有限公司
|
2024-12-31 | |
¥135.00 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |